Update on chemotherapy in the treatment of urothelial carcinoma

TheScientificWorldJournal

Volumn 11, Issue , 2011, Pages 1981-1994

  Costantini, Carrie ^a   Millard, Frederick ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

bladder cancer; chemotherapy; urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IXABEPILONE; METHOTREXATE; PACLITAXEL; PEMETREXED; VINBLASTINE; VINFLUNINE;

ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CYSTECTOMY; HUMAN; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; HUMANS; NEOPLASM METASTASIS; URINARY BLADDER NEOPLASMS;

EID: 81555226819     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2011/590175     Document Type: Article

References (87)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
2. Rosenberg J. E., Carroll P. R., Small E. J., Update on chemotherapy for advanced bladder cancer Journal of Urology 2005 174 1 14 20 (Pubitemid 40825662)
3. Stein J. P., Lieskovsky G., Cote R., Groshen S., Feng A. C., Boyd S., Skinner E., Bochner B., Thangathurai D., Mikhail M., Raghavan D., Skinner D. G., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients Journal of Clinical Oncology 2001 19 3 666 675 (Pubitemid 32120143)
4. Witte R. S., Elson P., Bono B., Knop R., Richardson R. R., Dreicer R., Loehrer P. J., Eastern cooperative oncology group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma Journal of Clinical Oncology 1997 15 2 589 593 (Pubitemid 27074226)
5. McCaffrey J. A., Hilton S., Mazumdar M., Sadan S., Kelly W. K., Scher H. I., Bajorin D. F., Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma Journal of Clinical Oncology 1997 15 5 1853 1857 (Pubitemid 27209514)
6. Lorusso V., Pollera C. F., Antimi M., Luporini G., Gridelli C., Frassineti G. L., Oliva C., Pacini M., De Lena M., A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer European Journal of Cancer 1998 34 8 1208 1212 (Pubitemid 28342111)
7. Albers P., Siener R., Haertlein M., Fallahi M., Haeutle D., Perabo F. G. E., Steiner G., Blatter J., Mueller S. C., Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinomaPrognostic factors for response and improvement of quality of life Onkologie 2002 25 1 47 52 (Pubitemid 34224993)
8. Vaughn D. J., Broome C. M., Hussain M., Gutheil J. C., Markowitz A. B., Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer Journal of Clinical Oncology 2002 20 4 937 940 (Pubitemid 34141835)
9. Joly F., Houédé N., Noal S., Chevreau C., Priou F., Chinet-Charrot P., Rolland F., Fléchon A., Henry-Amar M., Culine S., Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study Clinical Genitourinary Cancer 2009 7 2 E28 E33
10. Sweeney C. J., Roth B. J., Kabbinavar F. F., Vaughn D. J., Arning M., Curiel R. E., Obasaju C. K., Wang Y., Nicol S. J., Kaufman D. S., Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium Journal of Clinical Oncology 2006 24 21 3451 3457 (Pubitemid 46638903)
11. Galsky M. D., Mironov S., Iasonos A., Scattergood J., Boyle M. G., Bajorin D. F., Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma Investigational New Drugs 2007 25 3 265 270 (Pubitemid 46774696)
12. Dreicer R., Li S., Manola J., Haas N. B., Roth B. J., Wilding G., Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the eastern cooperative oncology group Cancer 2007 110 4 759 763 (Pubitemid 47257651)
13. Sridhar S., Canil C., Mukherjee S., Results of a phase II study of single agent nab-paclitaxel in platinum-refractory second line metastatic urothelial carcinoma (UC) Journal of Clinical Oncology 2011 29 supplement 7, abstract 241
14. Bellmunt J., Théodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., Caty A., Carles J., Jagiello-Gruszfeld A., Karyakin O., Delgado F. M., Hurteloup P., Winquist E., Morsli N., Salhi Y., Culine S., Von Der Maase H., Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract Journal of Clinical Oncology 2009 27 27 4454 4461
15. Lawrentschuk N., Colombo R., Hakenberg O. W., Lerner S. P., Mnsson W., Sagalowsky A., Wirth M. P., Prevention and management of complications following radical cystectomy for bladder cancer European Urology 2010 57 6 983 1001
16. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists The Lancet 1999 354 533 540
17. Hall R. R., Intl Collaboration of Trialists of the MRC Advanced Bladder Cancer Group, Updated results of a randomized controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer 21 Proceedings of the American Society of Clinical Oncology (ASCO '02) May 2002
18. Grossman H. B., Natale R. B., Tangen C. M., Speights V. O., Vogelzang N. J., Trump D. L., DeVere White R. W., Sarosdy M. F., Wood D. P., Raghavan D., Crawford E. D., Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer New England Journal of Medicine 2003 349 9 859 866 (Pubitemid 37025405)
19. Sherif A., Holmberg L., Rintala E., Mestad O., Nilsson J., Nilsson S., Malmstrm P. U., Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two nordic studies European Urology 2004 45 3 297 303 (Pubitemid 38221402)
20. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration European Urology 2005 48 202 205
21. Advanced Bladder Cancer Meta-Analysis, Neoadjuvant chemotherapy for invasive bladder cancer Cochrane Database of Systematic Reviews 2004 Chichester, UK John Wiley Sons
22. Winquist E., Kirchner T. S., Segal R., Chin J., Lukka H., Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis Journal of Urology 2004 171 2 I 561 569 (Pubitemid 38090430)
23. Herchenhorn D., Dienstmann R., Peixoto F. A., de Campos F. S., Santos V. O., Moreira D. M., Cardoso H., Small I. A., Ferreira C. G., Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma International Brazilian Journal of Urology 2007 33 5 630 638
24. Dash A., Pettus J. A., Herr H. W., Bochner B. H., Dalbagni G., Donat S. M., Russo P., Boyle M. G., Milowsky M. I., Bajorin D. F., A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 2008 113 9 2471 2477
25. Svatek R. S., Shariat S. F., Novara G., Skinner E. C., Fradet Y., Bastian P. J., Kamat A. M., Kassouf W., Karakiewicz P. I., Fritsche H. -M., Izawa J. I., Tilki D., Ficarra V., Volkmer B. G., Isbarn H., Dinney C. P., Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort British Journal of Urology International 2011 107 6 898 904
26. Studer U. E., Bacchi M., Biedermann C., Jaeger P., Kraft R., Mazzucchelli L., Markwalder R., Senn E., Sonntag R. W., Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial Journal of Urology 1994 152 1 81 84 (Pubitemid 24175706)
27. Skinner D. G., Daniels J. R., Russell C. A., Lieskovsky G., Boyd S. D., Nichols P., Kern W., Sakamoto J., Krailo M., Groshen S., The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial Journal of Urology 1991 145 3 459 467
28. Stockle M., Meyenburg W., Wellek S., Voges G., Gertenbach U., Thuroff J. W., Huber C., Hohenfellner R., Yagoda A., Droller M. J., Vogelzang N. J., Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study Journal of Urology 1992 148 2 I 302 307
29. Stckle M., Wellek S., Meyenburg W., Voges G. E., Fischer U., Gertenbach U., Throff J. W., Huber C., Hohenfellner R., Radical cystectomy with or without adjuvant polychemotherapy for non- organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement Urology 1996 48 6 868 875
30. Lehmann J., Franzaring L., Throff J., Wellek S., Stckle M., Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer British Journal of Urology International 2006 97 1 42 47
31. Lehmann J., Retz M., Wiemers C., Beck J., Throff J., Weining C., Albers P., Frohneberg D., Becker T., Funke P. -J., Walz P., Langbein S., Reiher F., Schiller M., Miller K., Roth S., Klble T., Sternberg D., Wellek S., Stckle M., Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95) Journal of Clinical Oncology 2005 23 22 4963 4974 (Pubitemid 46224002)
32. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration European Urology 2005 48 189 199
33. Ruggeri E. M., Giannarelli D., Bria E., Carlini P., Felici A., Nelli F., Gallucci M., Cognetti F., Pollera C. F., Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies Cancer 2006 106 4 783 788 (Pubitemid 43238444)
34. Svatek R. S., Shariat S. F., Lasky R. E., Skinner E. C., Novara G., Lerner S. P., Fradet Y., Bastian P. J., Kassouf W., Karakiewicz P. I., Fritsche H. M., Mller S. C., Izawa J. I., Ficarra V., Sagalowsky A. I., Schoenberg M. P., Siefker-Radtke A. O., Millikan R. E., Dinney C. P. N., The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder Clinical Cancer Research 2010 16 17 4461 4467
35. Cognetti F., Ruggeri E. M., Felici A., Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial 5023, abstracts 26 Proceedings of the American Society of Clinical Oncology (ASCO '08) 2008
36. Stadler W.M., Lerner S. P., Groshen S., Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer (UBC) 5017, abstracts 27 Proceedings of the American Society of Clinical Oncology (ASCO '09) 2009
37. Paz-Ares L. G., Solsona E., Esteban E., Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study LBA4518, abstracts 28 Proceedings of the American Society of Clinical Oncology (ASCO '10) 2010
38. Sternberg C. N., EORTC 30994 Summary. 2011
39. Rene N. J., Cury F. B., Souhami L., Conservative treatment of invasive bladder cancer Current Oncology 2009 16 4 36 47
40. Rdel C., Grabenbauer G. G., Khn R., Papadopoulos T., Dunst J., Meyer M., Schrott K. M., Sauer R., Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results Journal of Clinical Oncology 2002 20 14 3061 3071 (Pubitemid 34791095)
41. Coppin C. M. L., Gospodarowicz M. K., James K., Tannock I. F., Zee B., Carson J., Pater J., Sullivan L. D., Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation Journal of Clinical Oncology 1996 14 11 2901 2907 (Pubitemid 26371447)
42. James N. D., Hussain S. A., Hall E., Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004) 4517, abstracts 28 Proceedings of the American Society of Clinical Oncology (ASCO '10) 2010
43. Shipley W. U., Kaufman D. S., Zehr E., Heney N. M., Lane S. C., Thakral H. K., Althausen A. F., Zietman A. L., Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer Urology 2002 60 1 62 67 (Pubitemid 34722947)
44. Shipley W. U., Winter K. A., Kaufman D. S., Lee W. R., Heney N. M., Tester W. R., Donnelly B. J., Venner P. M., Perez C. A., Murray K. J., Doggett R. S., True L. D., Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03 Journal of Clinical Oncology 1998 16 11 3576 3583 (Pubitemid 28506771)
45. Zietman A. L., Shipley W. U., Kaufman D. S., Zehr E. M., Heney N. M., Althausen A. F., McGovern F. J., A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer Journal of Urology 1998 160 5 1673 1677 (Pubitemid 128746736)
46. Weiss C., Engehausen D. G., Krause F. S., Papadopoulos T., Dunst J., Sauer R., Rdel C., Radiochemotherapy with cisplatin and 5-Fluorouracil after transurethral surgery in patients with bladder cancer International Journal of Radiation Oncology Biology Physics 2007 68 4 1072 1080 (Pubitemid 47048579)
47. Kaufman D. S., Winter K. A., Shipley W. U., Heney N. M., Chetner M. P., Souhami L., Zlotecki R. A., Sause W. T., True L. D., The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response Oncologist 2000 5 6 471 476
48. Kaufman D. S., Winter K. A., Shipley W. U., Heney N. M., Wallace H. J., Toonkel L. M., Zietman A. L., Tanguay S., Sandler H. M., Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy Urology 2009 73 4 833 837
49. Hagan M. P., Winter K. A., Kaufman D. S., Wajsman Z., Zietman A. L., Heney N. M., Toonkel L. M., Jones C. U., Roberts J. D., Shipley W. U., RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy International Journal of Radiation Oncology Biology Physics 2003 57 3 665 672 (Pubitemid 37194292)
50. Kent E., Sandler H., Montie J., Lee C., Herman J., Esper P., Fardig J., Smith D. C., Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial Journal of Clinical Oncology 2004 22 13 2540 2545 (Pubitemid 41103741)
51. Sangar V. K., McBain C. A., Lyons J., Ramani V. A. C., Logue J. P., Wylie J. P., Clarke N. W., Cowan R. A., Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer International Journal of Radiation Oncology Biology Physics 2005 61 2 420 425 (Pubitemid 40164436)
52. Choudhury A., Swindell R., Logue J. P., Elliott P. A., Livsey J. E., Wise M., Symonds P., Wylie J. P., Ramani V., Sangar V., Lyons J., Bottomley I., McCaul D., Clarke N. W., Kiltie A. E., Cowan R. A., Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer Journal of Clinical Oncology 2011 29 6 733 738
53. Loehrer P. J., Einhorn L. H., Elson P. J., Crawford E. D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M. F., Lowe B. A., Blumenstein B., Trump D., A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study Journal of Clinical Oncology 1992 10 7 1066 1073
54. Logothetis C. J., Dexeus F. H., Finn L., Sella A., Amato R. J., Ayala A. G., Kilbourn R. G., A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors Journal of Clinical Oncology 1990 8 6 1050 1055 (Pubitemid 20200193)
55. Sternberg C. N., De Mulder P. H. M., Schornagel J. H., Théodore C., Fossa S. D., Van Oosterom A. T., Witjes F., Spina M., Van Groeningen C. J., De Balincourt C., Collette L., Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924 Journal of Clinical Oncology 2001 19 10 2638 2646 (Pubitemid 32441368)
56. Saxman S. B., Propert K. J., Einhorn L. H., Crawford E. D., Tannock I., Raghavan D., Loehrer P. J., Trump D., Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study Journal of Clinical Oncology 1997 15 7 2564 2569 (Pubitemid 27289886)
57. Bamias A., Aravantinos G., Deliveliotis C., Bafaloukos D., Kalofonos C., Xiros N., Zervas A., Mitropoulos D., Samantas E., Pectasides D., Papakostas P., Gika D., Kourousis C., Koutras A., Papadimitriou C., Bamias C., Kosmidis P., Dimopoulos M. A., Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group Journal of Clinical Oncology 2004 22 2 220 228 (Pubitemid 41095085)
58. Von Der Maase H., Andersen L., Crin L., Weinknecht S., Dogliotti L., Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial Annals of Oncology 1999 10 12 1461 1465 (Pubitemid 30017056)
59. Moore M. J., Winquist E. W., Murray N., Tannock I. F., Huan S., Bennett K., Walsh W., Seymour L., Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology 1999 17 9 2876 2881 (Pubitemid 29415247)
60. Kaufman D., Raghavan D., Carducci M., Levine E. G., Murphy B., Aisner J., Kuzel T., Nicol S., Oh W., Stadler W., Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer Journal of Clinical Oncology 2000 18 9 1921 1927 (Pubitemid 30261930)
61. Von der Maase H., Hansen S. W., Roberts J. T., Dogliotti L., Oliver T., Moore M. J., Bodrogi I., Albers P., Knuth A., Lippert C. M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S. P., Roychowdhury D. F., Tomlin I., Visseren-Grul C. M., Conte P. F., Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study Journal of Clinical Oncology 2000 18 17 3068 3077
62. Von Der Maase H., Sengelov L., Roberts J. T., Ricci S., Dogliotti L., Oliver T., Moore M. J., Zimmermann A., Arning M., Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer Journal of Clinical Oncology 2005 23 21 4602 4608 (Pubitemid 46224062)
63. Bellmunt J., Guillem V., Paz-Ares L., Gonzalez-Larriba J. L., Carles J., Batiste-Alentorn E., Saenz A., Lopez-Brea M., Font A., Nogue M., Bastus R., Climent M. A., De la Cruz J. J., Albanell J., Banus J. M., Gallardo E., Diaz-Rubio E., Cortes-Funes H., Baselga J., Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium Journal of Clinical Oncology 2000 18 18 3247 3255
64. Bellmunt J., von der Maase H., Mead G. M., Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study LBA5030, abstracts 25 Proceedings of the American Society of Clinical Oncology (ASCO '07) 2007
65. Petrioli R., Frediani B., Manganelli A., Barbanti G., De Capua B., De Lauretis A., Salvestrini F., Mondillo S., Francini G., Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study Cancer 1996 77 2 344 351
66. Bellmunt J., Ribas A., Eres N., Albanell J., Almanza C., Bermejo B., Solé L. A., Baselga J., Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 1997 80 10 1966 1972 (Pubitemid 27479792)
67. Dreicer R., Manola J., Roth B. J., See W. A., Kuross S., Edelman M. J., Hudes G. R., Wilding G., Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology group Cancer 2004 100 8 1639 1645 (Pubitemid 38456340)
68. Dogliotti L., Carten G., Siena S., Bertetto O., Martoni A., Bono A., Amadori D., Onat H., Marini L., Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial European Urology 2007 52 1 134 141 (Pubitemid 46803003)
69. Galsky M. D., Iasonos A., Mironov S., Scattergood J., Boyle M. G., Bajorin D. F., Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function Cancer 2007 109 3 549 555 (Pubitemid 46190963)
70. De Santis M., Bellmunt J., Mead G., Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): phase III results of EORTC study 30986 LBA4519, abstracts 28 Proceedings of the American Society of Clinical Oncology (ASCO '10) 2010
71. Linardou H., Aravantinos G., Efstathiou E., Kalofonos C., Anagnostopoulos A., Deliveliotis C., Bafaloukos D., Athanasios Dimopoulos M., Bamias A., Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group Urology 2004 64 3 479 484 (Pubitemid 39200741)
72. Bellmunt J., De Wit R., Albanell J., Baselga J., A feasibility study of carboplatin with fixed dose of gemcitabine in unfit patients with advanced bladder cancer European Journal of Cancer 2001 37 17 2212 2215 (Pubitemid 33001291)
73. Vaughn D. J., Manola J., Dreicer R., See W., Levitt R., Wilding G., Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology group Cancer 2002 95 5 1022 1027 (Pubitemid 34925352)
74. Galsky M. D., Hahn N. M., Rosenberg J. E., Defining cisplatin ineligible patients with metastatic bladder cancer 238, abstracts 29 Proceedings of the American Society of Clinical Oncology (ASCO '11) 2011
75. Raj G. V., Iasonos A., Herr H., Donat S. M., Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer Journal of Clinical Oncology 2006 24 19 3095 3100 (Pubitemid 46638946)
76. Meluch A. A., Greco F. A., Burris H. A., O'Rourke T., Ortega G., Steis R. G., Morrissey L. H., Johnson V., Hainsworth J. D., Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the minnie pearl cancer research network Journal of Clinical Oncology 2001 19 12 3018 3024 (Pubitemid 32565438)
77. Li J., Juliar B., Yiannoutsos C., Ansari R., Fox E., Fisch M. J., Einhorn L. H., Sweeney C. J., Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology group study Journal of Clinical Oncology 2005 23 6 1185 1191 (Pubitemid 46202275)
78. Sternberg C. N., Calabr F., Pizzocaro G., Marini L., Schnetzer S., Sella A., Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy Cancer 2001 92 12 2993 2998 (Pubitemid 33136193)
79. Albers P., Park S.-I., Niegisch G., Fechner G., Steiner U., Lehmann J., Heimbach D., Heidenreich A., Fimmers R., Siener R., Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99] Annals of Oncology 2011 22 2 288 294
80. Vergnenégre A., Tillon J., Corre R., Barlés F., Berard H., Vernejoux J.-M., Le Caer H., Fournel P., Marin B., Chouad C., A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 study) Journal of Thoracic Oncology 2009 4 3 364 370
81. Dreicer R., Li H., Cooney M. M., Wilding G., Roth B. J., Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group Cancer 2008 112 12 2671 2675 (Pubitemid 351969210)
82. Kanai K., Kikuchi E., Ohigashi T., Miyajima A., Nakagawa K., Nakashima J., Oya M., Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy International Journal of Clinical Oncology 2008 13 6 510 514
83. Suyama T., Ueda T., Fukasawa S., Imamura Y., Nakamura K., Miyasaka K., Sazuka T., Egoshi K. I., Nihei N., Hamano M., Ichikawa T., Maruoka M., Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma Japanese Journal of Clinical Oncology 2009 39 4 244 250
84. Krege S., Rembrink V., Brgermann C. H., Otto T., Rubben H., Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study Journal of Urology 2001 165 1 67 71
85. Hussain M. H. A., MacVicar G. R., Petrylak D. P., Dunn R. L., Vaishampayan U., Lara P. N., Chatta G. S., Nanus D. M., Glode L. M., Trump D. L., Chen H., Smith D. C., Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial Journal of Clinical Oncology 2007 25 16 2218 2224 (Pubitemid 46954646)
86. Neal D. E., Sharples L., Smith K., Fennelly J., Hall R. R., Harris A. L., The epidermal growth factor receptor and the prognosis of bladder cancer Cancer 1990 65 7 1619 1625 (Pubitemid 20106125)
87. Gallagher D. J., Milowsky M. I., Gerst S. R., Ishill N., Riches J., Regazzi A., Boyle M. G., Trout A., Flaherty A. M., Bajorin D. F., Phase II study of sunitinib in patients with metastatic urothelial cancer Journal of Clinical Oncology 2010 28 8 1373 1379